Luveltamab tazevibulin
- Generic Name
- Luveltamab tazevibulin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with Relapsed/Refractory CBFA2T3::GLIS2 AML
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06679582
- Locations
- 🇺🇸
Childrens Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT06555263
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸HealthPartners Cancer Research Center, St. Paul, Minnesota, United States
🇺🇸Florida Cancer Specialists, Lake Mary, Florida, United States
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05870748
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Ohio State University Center, Columbus, Ohio, United States
🇺🇸Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.